Over the last three decades, rapid progress in molecular biology has led to nucleic acids, such as plasmid DNA (pDNA), messenger RNA (mRNA) and, small interfering/silencing RNA (siRNA), being proposed for use as therapeutic agents. Our latest whitepaper underlines recent work in the field and details the extensive research [...]
Our CEO, Nigel Theobald, recently provided an update on our Nuvec® program following the release of our interim results. You can watch the full interview with Proactive London's Andrew Scott below or visit the website: https://bit.ly/2lU6O78. https://www.youtube.com/watch?time_continue=776&v=TJVlEOs8TEE
Our CEO, Nigel Theobald, recently caught up with The Medicine Maker to discuss the story behind N4 Pharma and give his advice to entrepreneurs in the pharmaceutical industry. Click here to create your logins and read the full article.
N4 Pharma has been featured in the latest issue of BioPharm International.
We recently joined a full house of attendees at CrownBio’s annual conference.
Nigel Theobald, CEO of N4 Pharma, has spoken to Dr. Kevin Robinson at Manufacturing Chemist magazine about how the company has developed Nuvec® and the impact it could have for vaccines and cancer treatments.
N4 Pharma has been featured in the latest issue of SHARES Magazine.
2019 is set to be a significant year for the development of drug delivery systems, particularly focused on cancer immunotherapy.
A unique non-viral adjuvant delivery system for vaccines and cancer treatments.
Our latest research has demonstrated that Nuvec® loaded with pDNA encoding the ovalbumin (OVA) antigen triggered an immune response that was sufficient to have produced strong levels of antibodies specific for OVA.
